Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study backs homocysteine and Alzheimer's link:

This article was originally published in Clinica

Executive Summary

Results from a study have provided more evidence to support the link between elevated blood levels of homocysteine and Alzheimer's disease (AD). US scientists at Boston University found that homocysteine levels that are greater than 14 mmol/litre doubled the chance of developing AD, and each 5 mmol/litre elevation increased the risk by 40%. The analysis also showed that people with consistently high levels of the marker were at highest risk for dementia and AD. The findings appear in The New England Journal of Medicine (February 14).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel